<?xml version='1.0' encoding='utf-8'?>
<document id="23370354"><sentence text="Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers."><entity charOffset="70-82" id="DDI-PubMed.23370354.s1.e0" text="Pioglitazone" /></sentence><sentence text="Pioglitazone, a peroxisome proliferator-activated receptor-Î³ agonist, is indicated for the treatment of type 2 diabetes"><entity charOffset="0-12" id="DDI-PubMed.23370354.s2.e0" text="Pioglitazone" /></sentence><sentence text=" Pioglitazone undergoes hepatic metabolism by cytochrome P450 2C8 (CYP2C8) and interindividual variability exists in pioglitazone disposition and response"><entity charOffset="1-13" id="DDI-PubMed.23370354.s3.e0" text="Pioglitazone" /><entity charOffset="117-129" id="DDI-PubMed.23370354.s3.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.23370354.s3.e0" e2="DDI-PubMed.23370354.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23370354.s3.e0" e2="DDI-PubMed.23370354.s3.e1" /></sentence><sentence text=" In previous analyses, it has been shown that the CYP2C8*3 polymorphism significantly impacts pioglitazone pharmacokinetics in humans"><entity charOffset="94-106" id="DDI-PubMed.23370354.s4.e0" text="pioglitazone" /></sentence><sentence text=" The purpose of this investigation was to develop a population pharmacokinetic model using nonlinear mixed effects analysis to evaluate and quantify the effect of CYP2C8*3, demographic, and clinical variables on interindividual variability in pioglitazone pharmacokinetics in nondiabetic adults"><entity charOffset="243-255" id="DDI-PubMed.23370354.s5.e0" text="pioglitazone" /></sentence><sentence text=" Data were obtained from 31 healthy volunteers (n=16 CYP2C8*1/*1, n=15 CYP2C8*3 carriers) who had previously participated in the monotherapy phase of a pioglitazone drug-drug interaction study"><entity charOffset="152-164" id="DDI-PubMed.23370354.s6.e0" text="pioglitazone" /></sentence><sentence text=" Participants received a single 15 g dose of pioglitazone followed by a 48-h sampling period"><entity charOffset="45-57" id="DDI-PubMed.23370354.s7.e0" text="pioglitazone" /></sentence><sentence text=" A two-compartment model with first order absorption and elimination (Akaike Information Criteria (AIC)=2889) showed a better fit for pioglitazone than a one-compartment model (AIC=3008)"><entity charOffset="134-146" id="DDI-PubMed.23370354.s8.e0" text="pioglitazone" /></sentence><sentence text=" Covariate analysis revealed that CYP2C8*3 had a significant effect on pioglitazone central compartment clearance (CL/F; p=0"><entity charOffset="71-83" id="DDI-PubMed.23370354.s9.e0" text="pioglitazone" /><entity charOffset="118-119" id="DDI-PubMed.23370354.s9.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.23370354.s9.e0" e2="DDI-PubMed.23370354.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23370354.s9.e0" e2="DDI-PubMed.23370354.s9.e1" /></sentence><sentence text="0005) and intercompartmental clearance (Q/F; p=0"><entity charOffset="42-43" id="DDI-PubMed.23370354.s10.e0" text="F" /></sentence><sentence text="004)" /><sentence text=" Pioglitazone CL/F and Q/F were 52% and 286% higher, respectively, in carriers of the CYP2C8*3 allele than in CYP2C8*1 homozygotes"><entity charOffset="1-13" id="DDI-PubMed.23370354.s12.e0" text="Pioglitazone" /><entity charOffset="17-18" id="DDI-PubMed.23370354.s12.e1" text="F" /><entity charOffset="25-25" id="DDI-PubMed.23370354.s12.e2" text="F" /><pair ddi="false" e1="DDI-PubMed.23370354.s12.e0" e2="DDI-PubMed.23370354.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23370354.s12.e0" e2="DDI-PubMed.23370354.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23370354.s12.e0" e2="DDI-PubMed.23370354.s12.e2" /><pair ddi="false" e1="DDI-PubMed.23370354.s12.e1" e2="DDI-PubMed.23370354.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23370354.s12.e1" e2="DDI-PubMed.23370354.s12.e2" /></sentence><sentence text=" Furthermore, inclusion of CYP2C8*3 as a covariate on CL/F and Q/F decreased interindividual variability in these parameters by 5"><entity charOffset="1-1" id="DDI-PubMed.23370354.s13.e0" text="F" /><entity charOffset="57-57" id="DDI-PubMed.23370354.s13.e1" text="F" /><entity charOffset="65-65" id="DDI-PubMed.23370354.s13.e2" text="F" /><pair ddi="false" e1="DDI-PubMed.23370354.s13.e0" e2="DDI-PubMed.23370354.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23370354.s13.e0" e2="DDI-PubMed.23370354.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23370354.s13.e0" e2="DDI-PubMed.23370354.s13.e2" /><pair ddi="false" e1="DDI-PubMed.23370354.s13.e1" e2="DDI-PubMed.23370354.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23370354.s13.e1" e2="DDI-PubMed.23370354.s13.e2" /></sentence><sentence text="2% and 14%, respectively" /><sentence text=" Other variables (e" /><sentence text="g" /><sentence text=", sex, body weight) were not significant covariates on pioglitazone pharmacokinetics in the model"><entity charOffset="55-67" id="DDI-PubMed.23370354.s17.e0" text="pioglitazone" /></sentence><sentence text=" In summary, CYP2C8*3 significantly affected pioglitazone CL/F, Q/F, and interindividual variability in these parameters in this healthy volunteer cohort"><entity charOffset="61-62" id="DDI-PubMed.23370354.s18.e0" text="F" /><entity charOffset="66-67" id="DDI-PubMed.23370354.s18.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.23370354.s18.e0" e2="DDI-PubMed.23370354.s18.e0" /><pair ddi="false" e1="DDI-PubMed.23370354.s18.e0" e2="DDI-PubMed.23370354.s18.e1" /></sentence><sentence text="" /></document>